RSS-Feed abonnieren
DOI: 10.1055/a-2223-2790
Association Between VEGF-460C/T Gene Polymorphism and Risk of Diabetic Retinopathy in Type 2 Diabetes Mellitus: A Meta-Analysis
![](https://www.thieme-connect.de/media/hmr/202403/lookinside/thumbnails/2023-07-0277_10-1055-a-2223-2790-1.jpg)
Abstract
The aim of the study was to investigate the relationship between VEGF-460C/T polymorphism and susceptibility to diabetic retinopathy (DR) in type 2 diabetes mellitus (T2DM) by meta-analysis. A comprehensive search was conducted across six databases until September 2023 to identify studies examining the association between VEGF-460C/T polymorphism and susceptibility to DR. Data process was performed by Stata 15.0 software. Eight studies were included, involving 1463 patients with DR. In the overall analysis, the difference was statistically significant only in the homozygous model (CC vs. TT: OR=1.86, p=0.048). A subgroup analysis of 6 papers with genotype frequency satisfying HWE in the control group indicated significant differences among the allele (C vs. T: OR=1.34, p=0.037), recessive (CC vs. CT+TT: OR=1.96, p=0.022) and homozygous (CC vs. TT: OR=2.28, p=0.015) models. However, in the dominant and heterozygous models, the difference was not statistically significant. The sensitivity of the HWE-based subgroup analysis showed that the conclusions in other gene models except the heterozygote model were not robust. This meta-analysis indicated that VEGF-460C/T gene polymorphism is associated with susceptibility to DR in T2DM. Allele C and genotype CC at the VEGF-460C/T locus are associated with an increased risk of DR in T2DM. However, considering that the results are not robust, more trials involving more rigorous design are needed to verify the findings of this review in the future.
Publikationsverlauf
Eingereicht: 04. Juli 2023
Angenommen nach Revision: 05. Dezember 2023
Accepted Manuscript online:
05. Dezember 2023
Artikel online veröffentlicht:
25. Januar 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart,
Germany
-
References
- 1 Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet (London, England) 2010; 376: 124-136
- 2 Teo ZL, Tham YC, Yu M. et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology 2021; 128: 1580-1591
- 3 Hammes H. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. Diabetologia 2018; 61: 29-38
- 4 Safi SZ, Qvist R, Kumar S. et al. Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets. Biomed Res Int 2014; 801269
- 5 Zhang J, Zhang J, Zhang C. et al. Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications. Cells (Basel) 2022; 11: 3362
- 6 Madonna R, Balistreri CR, Geng YJ. et al. Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches. Vasc Pharmacol 2017; 90: 1-7
- 7 Leley SP, Ciulla SP, Bhatwadekar AD. Diabetic retinopathy in the aging population: a perspective of pathogenesis and treatment. Clin Interv Aging 2021; 16: 1367-1378
- 8 Heng LZ, Comyn O, Peto T. et al. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabet Med 2013; 30: 640-650
- 9 Oshitari T. The pathogenesis and therapeutic approaches of diabetic neuropathy in the retina. Int J Mol Sci 2021; 22: 9050
- 10 Maturi RK, Glassman AR, Josic K. et al. Effect of intravitreous anti-vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol W randomized clinical trial. JAMA Ophthalmol 2021; 139: 701-712
- 11 Maturi RK, Glassman AR, Josic K. et al. Four-year visual outcomes in the protocol W randomized trial of intravitreous aflibercept for prevention of vision-threatening complications of diabetic retinopathy. JAMA 2023; 329: 376-385
- 12 Caldwell RB, Bartoli M, Behzadian MA. et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes/Metab Res Rev 2003; 19: 442-455
- 13 Radovich M, Hancock BA, Kassem N. et al. Resequencing of the vascular endothelial growth factor promoter reveals haplotype structure and functional diversity. Angiogenesis 2010; 13: 211-218
- 14 Xie XJ, Yang YM, Jiang JK. et al. Association between the vascular endothelial growth factor single nucleotide polymorphisms and diabetic retinopathy risk: a meta-analysis. J Diabetes 2017; 9: 738-753
- 15 Gong JY, Sun YH. Association of VEGF gene polymorphisms with diabetic retinopathy: a meta-analysis. Plos One 2013; 8: e84069
- 16 Han L, Zhang L, Xing W. et al. The associations between VEGF gene polymorphisms and diabetic retinopathy susceptibility: a meta-analysis of 11 case-control studies. J Diabetses Res 2014; 805801
- 17 Yang Q, Zhang Y, Zhang X. et al. Association of VEGF gene polymorphisms with susceptibility to diabetic retinopathy: a systematic review and meta-analysis. Horm Metab Res 2020; 52: 264-279
- 18 Hu L, Gong C, Chen X. et al. Associations between vascular endothelial growth factor gene polymorphisms and different types of diabetic retinopathy susceptibility: a systematic review and meta-analysis. J Diabetes Res. 2021 7059139.
- 19 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed.) 2021; 372: n71
- 20 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-605
- 21 Crawford TN, Alfaro DV, Kerrison JB. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev 2009; 5: 8-13
- 22 Yang X, Deng Y, Gu H. et al. Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes. Mol Vis 2011; 17: 3088-3096
- 23 Szaflik JP, Wysocki T, Kowalski M. et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefe's Archiv. Clin Exp Ophthalmol 2008; 246: 39-43
- 24 Paine SK, Basu A, Mondal LK. et al. Association of vascular endothelial growth factor, transforming growth factor beta, and interferon gamma gene polymorphisms with proliferative diabetic retinopathy in patients with type 2 diabetes. Mol Vis 2012; 18: 2749-2757.
- 25 Yang X, Deng Y, Gu H. et al. Candidate gene association study for diabetic retinopathy in Chinese patients with type 2 diabetes. Mol Vis 2014; 20: 200-214
- 26 Yuan Y, Wen Z, Guan Y. et al. The relationships between type 2 diabetic retinopathy and VEGF-634G/C and VEGF-460C/T polymorphisms in Han Chinese subjects. J Diabetes Complicat 2014; 28: 785-791
- 27 Khan N, Paterson AD, Roshandel D. et al. Association of IGF1 and VEGFA polymorphisms with diabetic retinopathy in Pakistani population. Acta Diabetol 2020; 57: 237-245
- 28 Jehanzeb M, Khan NU, Hussain M. et al. Association of candidate genes (ALR2, RAGE, and VEGF) polymorphisms with diabetic retinopathy in type 2 diabetic patients of Khyber Pakhtunkhwa, Pakistan. Mol Biol Rep 2023; 50: 227-234
- 29 Wang XM, Jin CJ, Zhang T. et al. The association of gene polymorphism of vascular endothelial growth factor with diabetic retinopathy. Chin J Diabetes 2008; 16: 462-464
- 30 Patel S, Chen H, Tinkham NH. et al. Genetic susceptibility of diabetic retinopathy. Curr Diabetses Rep 2008; 8: 257-262
- 31 Koutras A, Kotoula V, Fountzilas G. Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer. Pharmacogenomics 2015; 16: 79-94
- 32 Liu X, Zhou X, Song W. et al. The diagnostic value of circulating VEGF in diabetic retinopathy in Asia: a systematic review and meta-analysis. Ophthal Epidemiol 2023; 30: 230-238
- 33 Iglicki M, González DP, Loewenstein A. et al. Next-generation anti-VEGF agents for diabetic macular oedema. Eye (London, England) 2022; 36: 273-277
- 34 Ai X, Yu P, Luo L. et al. Berberis dictyophylla F. inhibits angiogenesis and apoptosis of diabetic retinopathy via suppressing HIF-1α/VEGF/DLL-4/Notch-1 pathway. J Ethnopharmacol 2022; 296: 115453
- 35 Wang N, Zhang C, Xu Y. et al. Berberine improves insulin-induced diabetic retinopathy through exclusively suppressing Akt/mTOR-mediated HIF-1α/VEGF activation in retina endothelial cells. Int J Biol Sci 2021; 17: 4316-4326